# A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct07021963` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07021963](<https://clinicaltrials.gov/study/NCT07021963>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07021963

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07021963. Non-randomized; no masking; primary purpose treatment. Start 2025-07-04 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07021963, source copy `cardio:ctgov-nct07021963-2025-09-10`, retrieved 2026-10-31)
- Started: 2025-07-04 (actual) (ClinicalTrials.gov record NCT07021963, source copy `cardio:ctgov-nct07021963-2025-09-10`, retrieved 2026-10-31)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT07021963, source copy `cardio:ctgov-nct07021963-2025-09-10`, retrieved 2026-10-31)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT07021963, source copy `cardio:ctgov-nct07021963-2025-09-10`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07021963, source copy `cardio:ctgov-nct07021963-2025-09-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07021963-2025-09-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
- Condition: Hypertrophic Cardiomyopathy
- Intervention (Drug): HRS-1893 Tablet
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

## Provenance

Content hash: d45894e79327e2aa6aa2b3d71f03e291b4a59f622187bcc68bd41363ab8ae80d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
